NuCana PLC
NCNA0.660USD
0.000
Close 04/24, 16:00（ET）Quotes delayed by 15 min
3.75MMarket Cap
LossP/E TTM
More Details of NuCana PLC Company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Company Info
Company codeNCNA
Company nameNuCana PLC
IPO dateSep 28, 2017
Founded at1997
CEOMr. Hugh S. Griffith
Number of employees20
Security typeDepository Receipt
Fiscal year-endSep 28
AddressLochside House
CityEDINBURGH
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited Kingdom
Postal codeEH12 9DT
Phone4401313571111
Websitehttps://www.nucana.com/
Company codeNCNA
IPO dateSep 28, 2017
Founded at1997
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Donald (Don) Munoz
Mr. Donald (Don) Munoz
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sat, Mar 22
Update time: Sat, Mar 22
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Sofinnova Investments, Inc
3.51%
Abingworth Management Limited
2.35%
Susquehanna International Group, LLP
0.82%
Schonfeld Strategic Advisors LLC
0.79%
Acadian Asset Management LLC
0.75%
Other
91.78%
Shareholder Statistics
Shareholder
Proportion
Sofinnova Investments, Inc
3.51%
Abingworth Management Limited
2.35%
Susquehanna International Group, LLP
0.82%
Schonfeld Strategic Advisors LLC
0.79%
Acadian Asset Management LLC
0.75%
Other
91.78%
Type
Shareholder
Proportion
Venture Capital
5.86%
Investment Advisor
2.08%
Hedge Fund
1.60%
Research Firm
1.12%
Investment Advisor/Hedge Fund
0.78%
Individual Investor
0.22%
Other
88.33%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
50
678.81K
11.95%
+387.28K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
2023Q1
81
667.89K
31.87%
-504.63K
2022Q4
87
672.60K
32.11%
-559.71K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sofinnova Investments, Inc
199.52K
3.51%
+199.52K
--
Feb 14, 2025
Abingworth Management Limited
133.33K
2.35%
--
--
Dec 31, 2024
Susquehanna International Group, LLP
46.72K
0.82%
+46.72K
--
Dec 31, 2024
Schonfeld Strategic Advisors LLC
45.07K
0.79%
+45.07K
--
Dec 31, 2024
Acadian Asset Management LLC
42.41K
0.75%
+18.79K
+79.54%
Dec 31, 2024
Virtu Americas LLC
40.40K
0.71%
+40.40K
--
Dec 31, 2024
Baillie Gifford & Co.
36.70K
0.65%
--
--
Dec 31, 2024
Citadel Advisors LLC
25.00K
0.44%
+25.00K
--
Dec 31, 2024
Two Sigma Investments, LP
20.99K
0.37%
+20.99K
--
Dec 31, 2024
Glass Jacobson Wealth Advisors
15.00K
0.26%
--
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Date
Type
Ratio
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1